Joseph Pierre Aboumsallem: ET Treatment Enters a New Chapter
Joseph Pierre Aboumsallem, Drug Development Lead – siRNA Therapeutics, Postdoctoral Researcher, Project Manager at Erasmus MC, Project Manager at University Medical Center Groningen (UMCG), shared a post on LinkedIn about a recent article by Isabelle Plo and William Vainchenker, published in NEJM, adding:
“Amazing news!!
The FDA has approved ropeginterferon alfa-2b for essential thrombocythemia (ET), the first new treatment approval for the disease in nearly 30 years.
ET is a chronic myeloproliferative neoplasm driven by clonal haematopoiesis.
Persistent thrombocytosis increases the risk of thrombosis and bleeding, and treatment options remain limited for patients who do not respond to or cannot tolerate hydroxyurea.
In SURPASS-ET, 37.4% of patients treated with ropeginterferon achieved a durable composite response, including blood count control, no progression of splenomegaly, and no thrombotic or haemorrhagic events, sustained at 9 and 12 months. The corresponding rate with anagrelide was 3.6%.
The molecular responses across JAK2, CALR and MPL are also important. Controlling platelet counts is one part of treatment.
Reducing the burden of the underlying clone is a different proposition and has been a long-standing goal in MPN research.
It is good to see interferon biology, developed over decades, now translating into a new treatment option for patients with ET.”
Title: Myeloproliferative Neoplasms
Authors: Isabelle Plo, William Vainchenker
Stay updated with Hemostasis Today.
-
Sep 14, 2026, 15:53Leonard Valentino: Advancing a New Model of Patient-Led Research
-
Sep 14, 2026, 15:48Adishwar Rao: LAAC vs Oral Anticoagulation in Atrial Fibrillation
-
Sep 14, 2026, 15:36Lesley Van Wyk: Hemolytic Anemia Quick Revision – Tips and Tricks
-
Sep 14, 2026, 15:35Maha Othman: ISTH-BAT Reference Ranges Validated Across Five Continents in Children
-
Sep 14, 2026, 15:30Umberto Pensato։ Left Ventricular Dysfunction and DOAC Benefit in ESUS
-
Sep 14, 2026, 15:22Meral Kayikcioglu: Why Do Women and Men Differ in LDL-C Management?
-
Sep 14, 2026, 15:22James Crowley: The Complex Role of CRP in Cardiovascular Risk and Atherosclerosis
-
Sep 14, 2026, 15:16Factor XIII Deficiency An Often-Missed Bleeding Disorder
-
Sep 14, 2026, 15:07Raffaele Piccolo: Heparin Against Jellyfish Venom?